Latest Breaking News On - Soo young choi - Page 1 : comparemela.com

Monthly Review | Industrial Agriculture: Lessons from North Korea

This article will be released in full online March 12, 2023. According to most Western commentators, North Korea is an “enigma” plagued by “irrational”…

KAIST's Robo-Dog "RaiBo" runs through sandy beach

Robo-dog runs on sand with ease and speed

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

Press release content from PR Newswire. The AP news staff was not involved in its creation. Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA January 27, 2021 GMT INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in South Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.